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ThegeneULK1isanexcellentcandidateforCrohn’sdisease(CD)duetoitsroleinautophagy.Arecentstudyprovidedevidencefor
the involvement of ULK1 in the pathogenesis of CD (Henckaerts et al., 2011). We attempted to validate this association, using a
candidate gene SNP study of ULK1 in CD. We identiﬁed tagging SNPs and genotyped these SNPs using the Sequenom platform in
a Caucasian New Zealand dataset consisting of 406CD patients and 638 controls. In this sample, we were able to demonstrate an
association between CD and several diﬀerent ULK1 SNPs and haplotypes. Phenotypic analysis showed an association with age of
diagnosis 17–40 years and inﬂammatory behaviour. The ﬁndings of this study provide evidence to suggest that genetic variation in
ULK1 may play a role in interindividual diﬀerences in CD susceptibility and clinical outcome.
1.Introduction
Crohn’s disease (CD) is a form of inﬂammatory bowel
disease (IBD) characterized by chronic, relapsing gastroin-
testinal inﬂammation. It results from multiple genetic and
multipleenvironmentalriskfactors,operatingadditivelyand
interactively. In recent years, the search for genetic determi-
nants of CD has changed dramatically with the introduction
of the Genome Wide Association Study (GWAS) technology
from which results have been excellent. As well as helping
to identify multiple susceptibility loci involved in the genetic
susceptibility to CD, GWAS has also provided evidence for
the involvement of biological pathways such as autophagy.
Autophagy is a well-conserved regulatory process by which
protein and organelle turnover occurs in cells by autodi-
gestion through lysosomal degradation. The pathway can
interact with other vital processes such as programmed cell
death, inﬂammation, and immune mechanisms. Autophagy
has several roles in innate and adaptive immunity including
pattern recognition receptor signalling, regulation of cell
death, elimination of bacteria and viruses, and immune cell
homeostasis [1–3]. Thus, it is thought that CD may result
from a defective autophagy pathway causing an impaired
antibacterial response and so an ineﬀective control of bac-
terial infection, dysbiosis of the intestinal microbiota, and
chronic inﬂammation.
There are many genes in the autophagy pathway that
have been previously associated with CD. They code for pro-
teins involved in the detection of autophagic triggers (IRGM
[4–6], NOD2 [7–9], VDR [10], and DAP1 [11, 12]), orches-
trating autophagosome formation (ATG16L1 [13, 14]), or
autophagosomal maturation (LRRK2 [15]). Mutations in
these autophagy-related genes may lead to loss of autophagic
functionandthesubsequentdevelopmentofCrohn’sdisease.
Arecentstudyinvestigatinganumberofautophagygenes
fortheirinvolvementinCDhasdescribedanovelassociation
between Unc-51-like kinase-1 (ULK1) and CD [16]. ULK1 is
a serine/threonine protein kinase that plays a critical role in2 Gastroenterology Research and Practice
Table 1: Summary of clinical data of CD patients.
CD
Gender F 265 (65.6)
M 139 (34.4)
Age at diagnosis
<17 46 (12.6)
17 to 40 257 (70.2)
40< 63 (17.2)
CD behaviour
Inﬂammatory 201 (55.1)
Stricturing 118 (32.3)
Penetrating 46 (12.6)
CD location
Ileal 136 (37.2)
Colonic 119 (32.5)
Ileocolonic 111 (30.3)
Bowel resection N 270 (66.7)
Y 135 (33.3)
Other IBD family N 330 (89.7)
Y 38 (10.3)
Perianal disease N 329 (85.7)
Y 55 (14.3)
the initial stages of autophagy, although the exact molecular
mechanism is unknown.
Here, we attempted to validate the association of ULK1
with CD in a well-characterised case-control New Zealand
dataset. We considered not only allele and genotype frequen-
cies, but also the question as to whether genotype could pre-
dictphenotypesincethisisanessentialtoolinunderstanding
disease behaviour and future treatment requirements [17].
2. Methods
2.1. Samples. A total of 1044 subjects from New Zealand
wereincludedinthestudy:406CDpatientsand638controls.
All participants self-reported European ancestry.
Clinical records were analysed to conﬁrm diagnosis, and
IBD status was deﬁned using standard diagnostic criteria
[18].CaseswerephenotypedaccordingtotheMontrealClas-
siﬁcation systems. Clinical characteristics of the CD patients
are shown in Table 1.
Participants consented to collection of peripheral blood
or a buccal swab for DNA extraction and genotyping, and
DNA was extracted from the blood/buccal samples using
Qiagen DNA extraction kit and following the manufacturer’s
instructions.
T h es t u d yw a sc o n d u c t e du n d e re t h i c a lp r o t o c o lM E C /
04/12/011, authorised through the New Zealand Multi-
Region Human Ethics Committee. All study subjects gave in-
formed consent.
2.2. SNP Selection. Tag SNPs in ULK1 were selected using
HapMap release 28 and the tagger functionality within
Haploview with pairwise tagging to identify SNPs using an
r2 > 0.8 and a minor allele frequency >5%. As a result,
nine tag SNPs were selected for genotyping: rs10902469,
rs7133672, rs7953348, rs7488085, rs11616018, rs12303764,
rs4964879, rs3088051, and rs3923716.
2.3. Genotyping. Genotyping was performed with the Mas-
sARRAYandiPlexsystemsoftheSequenomgenotypingplat-
form (Sequenom, San Diego, CA), which uses the MALDI-
TOF primer extension assay [19, 20], according to manufac-
turers’ recommendations.
Assays were optimized in 24 samples consisting of 20 ref-
erence Centre d’Etude du Polymorphisme Humain (CEPH)
samples and 4 blanks.
All sample plates contained cases, controls, blanks,
CEPH, and duplicate samples. Quality control measures in-
cluded independent double genotyping and, where available,
comparison of our CEPH genotypes to those in the Hapmap
database (http://www.hapmap.org/).
2.4. Statistical Analysis. SNPs were tested for deviation from
HWE in both cases and controls using a chi-square good-
ness-of-ﬁt test. To determine if there were diﬀerences bet-
ween cases and controls, allele frequencies for each SNP were
analyzed using 2 × 2 chi-square tables.
Genotype and phenotype associations were assessed by
comparing allele frequencies between controls and patient
subgroups deﬁned using the clinical characteristics. These
analyses were carried out using R (R: a language and envi-
ronment for statistical computing, R Foundation for Statisti-
cal Computing, Vienna, Austria. ISBN 3–900051-07-0, URL
http://www.R-project.org/) and SAS (V9.1 SAS Institute.,
Cary, NC, USA).
To determine linkage disequilibrium (LD) between SNPs
and to deﬁne haplotype blocks, we uploaded our data into
Haploview [21]. Haplotype blocks were deﬁned using the
defaultalgorithm,whichusesconﬁdenceintervals[22].Hap-
lotype analysis was carried using HAPLO.SCORE in R to test
for association of these haplotypes with CD.
For all analyses we considered a P value less than 0.05 to
indicate statistical signiﬁcance.
The false discovery rate (FDR) was used to correct for
multiple testing [23, 24].
3. Results
Two SNPs, rs7133672 and rs4964879, failed in the geno-
typing assay. The remaining seven SNPs were all genotyped
successfully and were in Hardy-Weinberg equilibrium in
both cases and controls.
3.1. Association Analysis. From the seven genotyped SNPs,
we saw association with CD for two SNPs. The G allele of
SNP rs10902469 was more frequent (95.4%) in the cases
compared to controls (92.5%), OR = 1.69, P = 0.0084. The
T allele of SNP rs7488085 was more frequent (93.7%) in the
cases compared to controls (91.1%), OR = 1.46, P = 0.030.
These SNPs remain statistically signiﬁcant if we correct for
multiple testing using the false discovery rate. Genotype and
allelecounts/frequenciesandP valuesforallgenotypedSNPs
are shown in Table 2.Gastroenterology Research and Practice 3
Table 2: Genotype and allele counts (and frequencies) in CD patients and in controls.
SNP Case Control Case Control OR (955 CI) P
rs10902469
G/G 367 (90.8) 544 (0.86) G 771 (95.4) 1177 (92.5) 1.69 (1.14–2.50) 0.0084∗
C/G 37 (9.2) 89 (0.14) C 37 (4.6) 95 (7.5)
C/C 0 (0.00) 3 (0.00)
rs7953348
T/T 276 (69.0) 406 (65.8) T 663 (82.9) 993 (80.5) 1.17 (0.93–1.46) 0.17
C/T 111 (27.8) 181 (29.3) C 137 (17.1) 241 (19.5)
C/C 13 (3.3) 30 (4.9)
rs7488085
T/T 355 (87.7) 529 (82.8) T 759 (93.7) 1164 (91.1) 1.46 (1.03–2.06) 0.030∗
C/T 49 (12.1) 106 (16.6) C 51 (6.3) 114 (8.9)
C/C 1 (0.2) 4 (0.6)
rs11616018
T/T 281 (70.6) 419 (66.3) T 668 (83.9) 1022 (80.9) 1.23 (0.98–1.55) 0.078
C/T 106 (26.6) 184 (29.1) C 128 (16.1) 242 (19.1)
C/C 11 (2.8) 29 (4.6)
rs12303764
T/T 165 (40.8) 254 (40.3) T 515 (63.7) 788 (62.5) 1.06 (0.88–1.26) 0.58
G/T 185 (45.8) 280 (44.4) G 293 (36.3) 472 (37.5)
G/G 54 (13.4) 96 (15.2)
rs3088051
T/T 193 (47.7) 331 (52.2) T 560 (69.1) 921 (72.6) 1.20 (0.99–1.46) 0.086
C/T 174 (43.0) 259 (40.9) C 250 (30.9) 347 (27.4)
C/C 38 (9.4) 44 (6.9)
rs3923716
C/C 333 (82.4) 506 (79.9) C 735 (91.0) 1134 (89.6) 1.17 (0.86–1.59) 0.30
A/C 69 (17.1) 122 (19.3) A 173 (9.0) 132 (10.4)
A/A 2 (0.5) 5 (0.8)
∗Remain statistically signiﬁcant after applying a multiple testing correction using FDR.
3.2. Phenotypic Analysis. The two SNPs that were associated
with CD (rs10902469 and rs7488085) were both associated
with age of diagnosis 17 to 40 years (OR = 1.90, P = 0.010
and OR = 1.53, P = 0.044) and inﬂammatory disease (OR =
2.63, P = 0.002 and OR = 1.79, P = 0.018). SNP rs10902469
was also associated with colonic disease (OR = 2.33, P =
0.025).SNPrs3088051wasassociatedwithstricturing(OR =
1.45, P = 0.015) and ileal (OR = 1.34, P = 0.042) disease
and bowel resection (OR = 1.58, P = 0.002). The other
4 SNPs did not demonstrate any associations with any sub-
phenotypes. Full phenotype results are shown in Table 3.A l l
of the signiﬁcant ﬁndings remained signiﬁcant after multiple
testing correction, with the exception of the association of
rs7488085 with age of diagnosis 17–40.
3.3. Haplotypic Analysis. Figure 1 shows the LD plot for the
ULK1 SNPs in our New Zealand dataset. Five SNPs are in the
same haplotype block: rs10902469, rs7953348, rs7488085,
rs11616018, and rs12303764. Table 4 summarises haplotype
analysisresultsbutinbriefthreehaplotypeswerefoundtobe
statistically signiﬁcant in their association with CD. Haplo-
type CCCCT was protective in that it was more frequent in
the controls (0.066) compared to cases (0.036), P = 0.005.
H a p l o t y p eG C T T Tw a sp r o t e c t i v ei nt h a ti tw a sm o r ef r e q u -
ent in the controls (0.019) compared to cases (0.006), P =
0.038. Haplotype GTTTT was more frequent in the cases
(0.455) compared to controls (0.406), P = 0.027. However,
after applying multiple testing correction these haplotypes
were no longer statistically signiﬁcant.
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Figure 1: ULK1 LD plot.
4. Discussion
ULK1 is an autophagy gene that has recently been reported
for the ﬁrst time to be associated with CD [16]. In order to
conﬁrm the role of ULK1 in CD susceptibility we performed4 Gastroenterology Research and Practice
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Table 4: ULK1 haplotype analysis.
rs10902469 rs7953348 rs7488085 rs11616018 rs12303764 Hap-score P
Hap-frequency
Control Case
CC C C T −2.828 0.005 0.066 0.036
GC T T T −2.071 0.038 0.019 0.006
G T T T G 0.011 0.991 0.361 0.363
G C C C T 0.151 0.880 0.019 0.020
G C T C T 0.333 0.739 0.094 0.098
G T T T T 2.212 0.027 0.406 0.455
an independent association study in a New Zealand case–
control sample set. We were able to demonstrate evidence of
association for two SNPs. However, the associations we ob-
served were diﬀerent from those reported by the previous
study. Henckaerts et al. [16] had the strongest association
with CD for rs12303764, but this SNP was not associated
with CD in our samples. They also reported weaker associa-
tions for rs10902469, rs7953348, and rs3923716. From these
we only saw association in our dataset for rs10902469. We
also saw association with rs7488085, which was not geno-
typed in the previous study. To further determine whether
ULK1isaCDsusceptibilitygene,weexaminedthedata(data
not shown) from a recent CD genome-wide meta-analysis
[25] for SNPs in this gene. Three SNPs in ULK1 were in-
cluded in the analysis: rs11246867 that is LD (r2 = 1) with
rs10902469 that was associated with CD in both our study
and the study by Henckaerts et al. showed no association in
the GWAS meta-analysis, rs3923716 was associated with CD
in the study of Henckaerts et al. but not in our study and
likewise not in the GWAS meta-analysis, and rs3088051 was
not associated with CD neither in the study of Henckaerts et
al. nor our study (although there is a diﬀerence in cases and
controls which is approaching statistical signiﬁcance) but
showed association in the GWAS meta-analysis (uncorrected
nominal,P = 0.00068).Itisbynomeanscertainthatsupport
for ULK1 as a CD susceptibility gene requires the same pat-
tern of association to be obtained. Genetic heterogeneity,
variationinphenotypes,andlackofpowermayexplainsome
of the discrepancies. Further studies are needed in other
cohorts to determine the robustness of these observations in
diﬀerent populations and to be certain whether ULK1 can be
described as CD susceptibility gene.
Phenotypic analysis demonstrated association for the 2
CD associated SNPs with a young adult age at ﬁrst diagnosis
(17–40 years) and not with disease diagnosed after 40 years
nor with early-onset (paediatric) disease (before 17 years).
The age of diagnosis of CD in adults is known to have a
bimodal distribution: the ﬁrst peak occurs between the ages
of 15 and 30 years, and the second peak occurs between
the ages of 60 and 80 years [26]. Younger age-at-diagno-
sis patients represent a separate and often more severe phe-
notype of CD [27]. The diﬀerent phenotypes seen in the
diﬀerent age groups are likely to be as a result of each of
these groups having a diﬀerent genetic component to their
disease. The study we report here concludes that ULK1 has
a role in patients who are diagnosed as young adults and is
unlikely to be important in patients who are diagnosed after
40 years. Likewise there is no evidence to suggest ULK1 has
a role in paediatric CD, although this cannot be ruled out
entirely as the numbers in this group are small and so the
power to detect an association here is limited.
Phenotypic analysis also demonstrated association with
inﬂammatoryCDbehaviour.Intermsofdiseasebehaviorin-
ﬂammatory disease is the milder and less complicated form
and over time some patients may develop penetrating or
stricturing complications. So a strong association with in-
ﬂammatory disease is diﬃcult to interpret. But the associ-
ation of ULK1 with inﬂammation is not surprising. ULK1
plays a critical role in the initial stages of autophagy and
it is possible that genetic variation in this gene may result
in autophagy-mediated control of commensal bacteria being
compromised, subsequently leading to an intestinal inﬂam-
matory response to bacteria.
The results from phenotype analysis also suggested that
other subphenotypes may also be aﬀected as SNP rs3088051
demonstrated association with stricturing behaviour, ileal
location, and bowel resection. This SNP was not associated
with CD in the main case-control analysis. However there
was a diﬀerence in allele frequency between cases and con-
trols that was approaching statistical signiﬁcance.
In conclusion, the ﬁndings of this study provide some
evidence to suggest that genetic variation in ULK1 may play
a role in interindividual diﬀerences in CD susceptibility and
clinical outcome. However it remains unclear which variants
are most important. There could be other genetic variants
such as rare variants and/or copy number variations that
existatthislocusandareinLDwithoneormoreoftheSNPs
we have investigated. It is known that the ULK1 gene is loca-
ted in a region of copy number variation [28, 29]. Future
eﬀorts should aim to identify the causative variants in this
region by sequencing and functional experiments.
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